Summary: In a single-centre prospective randomized controlled trial of 180 adults with type 2 diabetes, an integrated cloud-hospital data platform combined with dietary management and individualized education videos lowered HbA1c at Week 12 versus routine standard care (6.9 plus or minus 0.9% vs 7.4 plus or minus 0.7%, P less than 0.01). Within the experimental arm, overweight or obese patients taking semaglutide alongside the platform achieved a 13.4% weight reduction.
PICO Summary
| Element | Detail |
|---|---|
| Population | 180 adults with type 2 diabetes; single-centre prospective randomized controlled trial, China. |
| Intervention | Integrated cloud-hospital data platform plus dietary management plus individualized diabetes education videos (Group B; n=90, 1:1 allocation). Overweight or obese patients in this arm could additionally receive semaglutide. |
| Comparison | Routine standard diabetes care without the platform or structured dietary management (Group A; n=90). |
| Outcome | Primary endpoints were change in HbA1c and body weight to Week 12. HbA1c 6.9 plus or minus 0.9% (intervention) vs 7.4 plus or minus 0.7% (control), P less than 0.01; higher rates of fasting glucose under 7 mmol/L and HbA1c under 7% in the intervention arm. Significant weight and BMI reduction in overweight or obese intervention patients; the semaglutide subgroup within this arm lost 13.4% of body weight at 12 weeks. No 95% confidence intervals, absolute risk reduction, or number-needed-to-treat were reported. |
Integrated data platform plus dietary management in type 2 diabetes
RCT · type 2 diabetes · 12 weeks
A digital data platform plus dietary management lowered Week-12 HbA1c by about half a point versus routine care in a small single-centre trial. The 13.4% weight loss reflects a semaglutide subgroup, not the platform itself.
Expert Commentary
This single-centre randomized trial offers a positive but modest signal that wrapping dietary management and tailored education videos around a digital data platform can improve short-term glycaemic control. The between-group HbA1c gap of roughly half a percentage point at twelve weeks is statistically significant and clinically plausible, and it is reassuring that the result was not driven by an implausibly large effect. Several caveats temper enthusiasm. The intervention is inherently open-label, since patients and clinicians cannot be blinded to receiving a digital platform and education videos, which leaves performance and ascertainment bias unaddressed. The single weighed limitation worth emphasising is that the headline 13.4% weight loss reflects a semaglutide subgroup nested within the experimental arm rather than a randomized comparison, so that figure reports the drug far more than the platform and should not be attributed to the digital tool. The sample is small, the setting is a single hospital, no confidence intervals or absolute effect measures are given, and durability beyond twelve weeks is untested. Can I use this with my patients? Cautiously, for motivated adults with type 2 diabetes who already engage with digital tools, as a complement to standard care rather than a replacement. Larger, multicentre, longer trials reporting absolute effects are needed before this platform earns routine adoption.
References
Liu X, Wang X, Xie M, Cao L. Application of the integrated data platform combined with dietary management for adults with diabetes: a prospective randomized controlled trial. J Diabetes Investig. 2024;15(11):1548-1555. doi:10.1111/jdi.14296
